Genpharmasec Ltd Stock Price Today (NSE: GENPHARMA)

Genpharmasec Ltd

1.18+0.00 (+0.00%)
Market Closed

Fundamental Score

...

Genpharmasec Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis

Genpharmasec Ltd share price today is 1.18, up +0.00% on NSE/BSE as of 23 June 2026. Genpharmasec Ltd (GENPHARMA) is a Small-cap company in the Trading & Distributors sector with a market capitalisation of 81.95 (Cr). The 52-week high for GENPHARMA share price is 2.20 and the 52-week low is 0.75. At a P/E ratio of 149.01x, GENPHARMA is currently trading above its industry average P/E of 35.45x. The company has a Return on Equity (ROE) of 1.90% and a debt-to-equity ratio of 0.17.

Genpharmasec Ltd Share Price Chart — NSE/BSE Historical Performance

No data
High
1.34
Low
1.09
Volume
3.7L
Change
-2.34%

Genpharmasec Ltd share price chart: -2.34% return over the past month. 52-week high ₹2.20, 52-week low ₹0.75.

Genpharmasec Ltd — Last 10 Trading Days

DateOpenHighLowCloseVolume
1.191.221.161.185.25L (Cr)
1.201.211.161.183.21L (Cr)
1.191.291.191.1910.73L (Cr)
1.311.331.251.256.32L (Cr)
1.341.341.251.3117.20L (Cr)
1.281.281.281.286.52L (Cr)
1.221.221.221.225.11L (Cr)
1.201.201.141.171.45L (Cr)
1.121.201.121.151.34L (Cr)
1.151.181.131.162.00L (Cr)

Genpharmasec Ltd — Last 12 Months Price History

MonthOpenHighLowCloseChange
1.201.221.161.18-1.67%
1.251.341.091.19-4.80%
0.801.340.801.22+52.50%
1.141.230.750.78-31.58%
1.111.451.111.18+6.31%
1.341.401.061.17-12.69%
1.531.561.291.31-14.38%
1.631.791.421.52-6.75%
1.901.921.581.61-15.26%
1.972.151.851.90-3.55%
2.002.201.911.94-3.00%
2.072.091.841.99-3.86%

AI Research Briefing

Powered by Gemini · 2026-04-17

Micro-cap pharma distributor's acquisition is a value trap until proven otherwise.

Research Confidence
5.0/10Moderate
DEBT TRAP TURNAROUNDBreakdown: 1M: -8.07%, 3M: -23.71%, 6M: -29.19%Expensive: P/E of 149.01x vs Industry P/E of 35.45x.

WHAT'S HAPPENING NOW (last 2-4 weeks)

No major catalysts found after live search. The company held an independent director's meeting on March 24, 2026, to review board performance and information flow.

CORE STORY (THE REAL GAME)

Why Now
  • Standalone revenue growth is strong, but misleading
  • Acquisition integration is a mess
  • Micro-cap liquidity risk
Potential Catalysts
  • Successful Derren Healthcare integration
  • New large distribution contracts
  • Significant cost-cutting measures
Key Risks
  • Micro-cap: high liquidity risk
  • Poor profitability despite revenue growth
  • Acquisition integration issues
Institutional Activity

No FII/DII activity. Promoter holding stable at 29.98%.

Macro Context

Trading & distribution sector faces intense competition and margin pressure.

Cash Flow Quality

No Free Cash Flow reported.

3–6 Month Outlook

Next 3-6 months hinge on Derren Healthcare turnaround. Expect continued volatility and potential for significant downside if integration fails.

Primary Thesis Risk

Derren Healthcare acquisition destroys shareholder value.

For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.

Returns & Performance

Poor

Return on Equity (ROE)

1.90%

Profit generated per ₹1 of shareholder equity

Poor

Return on Capital (ROCE)

3.35%

Returns generated on total capital deployed

Oper. Profit Margin (5Y Avg)

N/A

Average operating profit margin over 5 years

Dividend Yield

0.00%

Annual dividend as % of current share price

Genpharmasec Ltd Valuation Check

Poor

Price to Earnings (P/E)

149.01x

Share price ÷ earnings per share. Lower = cheaper

Poor

Industry Avg P/E

35.45x

Average P/E of all peers in this sector

Market-cap Classification
Small-cap
Higher growth potential with higher volatility.

Shareholding Pattern

Excellent

Promoter Holding

29.98%

% shares held by company founders/management

Poor

FII Holding

0.00%

% shares held by foreign institutional investors

Poor

DII Holding

0.00%

% held by domestic mutual funds, LIC, banks

Excellent

Promoter Pledged %

0.00%

% of promoter shares pledged as collateral — lower is safer

Growth Engine

Poor

Profit Growth (Quarterly YoY)

-268.57%

Net profit growth vs same quarter last year

Excellent

Revenue Growth (Quarterly YoY)

441.29%

Revenue growth vs same quarter last year

Revenue Growth (5-Year CAGR)

N/A

Compounded annual revenue growth over 5 years

EPS Growth (5-Year CAGR)

N/A

Earnings per share growth over 5 years

Net Profit Growth (5-Year CAGR)

N/A

Compounded annual net profit growth over 5 years

Balance Sheet Health

Excellent

Debt to Equity Ratio

0.17x

Total debt ÷ equity. Below 0.5 = financially healthy

Good

Interest Coverage Ratio

3.11x

EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably

Free Cash Flow (5-Year Total)

N/A

Cash left after capex over 5 years. Positive = self-funded growth

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Genpharmasec Ltd Fundamental Analysis & Valuation Benchmarking

Educational evaluation of GENPHARMA across key market metrics for learning purposes.

Positive Indicators

3 factors identified

Strong Revenue Growth (441.29%)

Observation: Healthy sales growth indicates market demand and execution capability.

Analysis: Revenue growth >15% suggests strong market position and growth potential.

Conservative Debt Levels (D/E: 0.17)

Observation: Low leverage provides financial flexibility and reduced risk.

Analysis: Conservative debt structure offers resilience during economic downturns.

Zero Share Pledging Risk

Observation: No promoter shares pledged as collateral.

Analysis: Absence of share pledging eliminates potential forced-selling pressure.

Risk Factors

6 factors identified

Below-Average Return on Equity (1.90%)

Observation: Returns on equity are below industry benchmarks.

Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.

Suboptimal ROCE (3.35%)

Observation: Returns on capital employed are below expectations.

Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.

Premium Valuation Risk (P/E: 149.01x)

Observation: High valuation multiples may limit upside potential.

Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.

Profit Decline Concern (-268.57%)

Observation: Significant year-over-year profit contraction observed.

Analysis: Declining profitability requires investigation into underlying causes.

Low Promoter Commitment (29.98%)

Observation: Reduced promoter stake may indicate limited confidence.

Analysis: Low promoter holding may raise questions about management commitment.

No Dividend Distribution

Observation: Company does not currently pay dividends to shareholders.

Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.

Genpharmasec Ltd vs Trading & Distributors Peers

Peer Comparison - Trading & Distributors

Compare Genpharmasec Ltd with 10 other companies in the same sector

11 companies
Company Info
Fundamental
Valuation
Profitability
Financial Health
Growth
Dividend
Company
Company name
Score
Bull Run comprehensive fundamental score based on 20+ metrics
Price
Current trading price of the stock
Market Cap
Total value of all shares in the market
P/E
Price per share divided by earnings per share
ROE
Net income divided by shareholder equity
ROCE
Earnings before interest and tax divided by capital employed
Debt/Eq
Total debt divided by total equity
Profit 5Y
Average annual profit growth over 5 years
Sales 5Y
Average annual sales growth over 5 years
Dividend
Annual dividend per share divided by price per share
11/100
1
₹81.95
149.0
Average
1.90%
Poor
3.35%
Poor
0.2
Excellent
0.00%
Redington Ltd...
REDINGTON532805
58.5/100
223
₹22049.92
16.1
Average
14.39%
Average
18.90%
Good
0.3
Excellent
17.72%
Excellent
14.06%
Good
2.41%
MMTC Ltd...
MMTC513377
32.1/100
66
₹8949.04
127.3
Average
5.87%
Poor
7.70%
Poor
0.0
Excellent
19.08%
Excellent
-86.52%
Poor
0.00%
MSTC Ltd...
MSTCLTD542597
63.7/100
439
₹3458.41
15.7
Average
28.37%
Excellent
29.26%
Excellent
0.2
Excellent
15.18%
Excellent
-24.06%
Poor
8.24%
24.7/100
405
₹3333.57
49.5
Average
26.05%
Excellent
27.44%
Excellent
0.2
Excellent
0.00%
11.1/100
154
₹2132.64
35.5
Average
17.05%
Good
15.42%
Good
0.2
Excellent
0.06%
34.8/100
379
₹1813.06
38.4
Average
9.28%
Poor
11.83%
Average
0.1
Excellent
0.00%
66.6/100
637
₹1297.46
519.0
Average
87.02%
Excellent
82.72%
Excellent
0.0
Excellent
158.76%
Excellent
66.77%
Excellent
0.00%
41.9/100
19
₹1111.34
402.7
Average
1.24%
Poor
2.46%
Poor
0.1
Excellent
61.76%
Excellent
35.83%
Excellent
0.00%
32.3/100
30300
₹1021.99
11.7
Average
9.31%
Poor
9.39%
Poor
0.0
Excellent
10.82%
Good
4.86%
Average
1.50%
62.3/100
46
₹811.32
6.4
Average
12.62%
Average
16.29%
Good
0.0
Excellent
28.35%
Excellent
61.75%
Excellent
0.00%

Genpharmasec Ltd PE Ratio History

Historical price-to-earnings ratio for GENPHARMA — last 5 years

YearEPS (₹)Price (₹)P/E Ratio
FY 20250.01₹1.31131x
FY 20240.01₹3.08308x

P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.

Genpharmasec Ltd Quarterly Performance

Latest quarterly metrics for GENPHARMA — revenue growth and profit growth vs same quarter last year

Revenue Growth (YoY)

441.29%

Latest quarter vs same quarter previous year

Net Profit Growth (YoY)

-268.57%

Latest quarter net profit vs same quarter previous year

5-Year Revenue CAGR

N/A

Compounded annual revenue growth over 5 years

5-Year Profit CAGR

N/A

Compounded annual net profit growth over 5 years

Genpharmasec Ltd Technical Indicators

SMA 50, SMA 200, RSI and volume signals for GENPHARMA — calculated from daily price history

49RSI 14
Neutral — RSI 49

Momentum is balanced — neither overbought nor oversold.

SMA 50
1
▲ Price above SMA 50 — Short-term bullish
SMA 200
1
▼ Price below SMA 200 — Long-term downtrend
30-Day Avg Volume
418K shares/day
Average daily traded volume over last 30 trading sessions

Technical indicators are for educational purposes only. Not investment advice.

Genpharmasec Ltd Financial Statements

Annual income statement, balance sheet and cash flow for Genpharmasec Ltd (GENPHARMA) — sourced from NSE/BSE filings.

Loading Financial Statements...

Fetching financial data for Genpharmasec Ltd

About GENPHARMA (Genpharmasec Ltd)

Genpharmasec Ltd is a dynamic enterprise operating at the intersection of pharmaceutical distribution and strategic investments. The company facilitates the seamless flow of vital ...pharmaceutical resources, connecting manufacturers with healthcare providers across the Indian landscape. Genpharmasec functions as a key logistical partner, ensuring the reliable and efficient delivery of medical necessities to where they are needed most. Beyond simply moving products, Genpharmasec is deeply engaged in understanding and navigating the complexities of the pharmaceutical market, adapting to its ever-evolving demands and regulatory framework. This proactive approach allows them to capitalize on emerging opportunities and provide tailored solutions to both suppliers and customers, fostering strong and enduring relationships within the healthcare ecosystem. A critical component of Genpharmasec's operations lies in its specialized distribution of diagnostic pharmaceutical equipment. Notably, this includes sophisticated tools like i-STAT analyzers and associated cartridges, essential for rapid blood analysis in critical care settings. By making these advanced diagnostic tools readily available, Genpharmasec directly contributes to the enhancement of patient care within Intensive Care Units (ICUs) and other acute care facilities. Their commitment to supplying cutting-edge diagnostic technology reflects a dedication to improving the speed and accuracy of medical assessments, enabling healthcare professionals to make informed decisions and deliver timely interventions. This targeted approach to diagnostic equipment distribution highlights Genpharmasec's focus on meeting the specialized needs of critical care environments. Furthermore, Genpharmasec Ltd engages in strategic investment and trading within the securities market. This facet of the company's activities demonstrates a diversification strategy aimed at generating value and strengthening its overall financial position. By actively participating in the financial markets, Genpharmasec seeks to optimize its resources and enhance its ability to support its core pharmaceutical distribution operations. This financial acumen enables the company to reinvest in its infrastructure, expand its product portfolio, and explore new avenues for growth and innovation. The synergy between its pharmaceutical distribution expertise and its investment activities positions Genpharmasec as a multifaceted organization with a long-term vision for sustainable success.

Company Details

Symbol:GENPHARMA
Industry:Trading & Distributors
Sector:Trading & Distributors

Key Leadership

Mr. Sohan Chaturvedi
CFO & Whole-Time Director
Mr. Hardik Makwana
Company Secretary & Compliance Officer

GENPHARMA Share Price: Frequently Asked Questions

What is the current share price of Genpharmasec Ltd?

Genpharmasec Ltd (GENPHARMA) trades at ₹1.18 on NSE and BSE. Market cap ₹81.95 (Cr). Educational data only.

What is the P/E ratio of Genpharmasec Ltd?

Genpharmasec Ltd has a P/E of 149.01x vs industry average 35.45x.

What is the Bull Run score for Genpharmasec Ltd?

Genpharmasec Ltd has a Bull Run score of 11/100 based on 25+ financial parameters.

Does Genpharmasec Ltd pay dividends?

Genpharmasec Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.

What is the ROE of Genpharmasec Ltd?

Genpharmasec Ltd has ROE of 1.90%. Higher ROE indicates better use of shareholder equity.

What is the debt-to-equity ratio of Genpharmasec Ltd?

Genpharmasec Ltd has debt-to-equity of 0.17.

Is Genpharmasec Ltd a good investment?

Bull Run gives Genpharmasec Ltd a score of 11/100. This is not investment advice — consult a SEBI-registered advisor.